Sumoylation of the zinc finger protein ZXDC enhances the function of its transcriptional activation domain

Biological Chemistry

Volumn 388, Issue 9, 2007, Pages 965-972

  Jambunathan, Srikarthika ^a   Fontes, Joseph D ^b  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Gene transcription; Histocompatibility; Sumoylation; Zinc finger

Indexed keywords

COACTIVATOR PROTEIN CLASS II TRANS ACTIVATOR; HISTONE DEACETYLASE 4; LYSINE; PROTEIN PIASY; REGULATOR PROTEIN; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER X LINKED DUPLICATED PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CELL STRAIN HEK293; COMPLEX FORMATION; ELECTROPHORETIC MOBILITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR WEIGHT; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; SUMOYLATION; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; PROTEIN STRUCTURE, TERTIARY; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 34547893048     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2007.106     Document Type: Article

References (35)

1. Al-Kandari, W., Jambunathan, S., Navalgund, V., Koneni, R., Freer, M., Parimi, N., Mudhasani, R., and Fontes, J.D. (2007a). ZXDC, a novel zinc finger protein that binds CIITA and activates MHC gene transcription. Mol. Immunol. 44, 311-321.
2. Al-Kandari, W., Koneni, R., Navalgund, V., Aleksandrova, A., Jambunathan, S., and Fontes, J.D. (2007b). The zinc finger proteins ZXDA and ZXDC form a complex that binds CIITA and regulates MHC II gene transcription. J. Mol. Biol. 369, 1175-1187.
3. Bohren, K.M., Nadkarni, V., Song, J.H., Gabbay, K.H., and Owerbach, D. (2004). A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem. 279, 27233-27238.
4. Boss, J.M. and Jensen, P.E. (2003). Transcriptional regulation of the MHC class II antigen presentation pathway. Curr. Opin. Immunol. 15, 105-111.
5. DeSandro, A.M., Nagarajan, U.M., and Boss, J.M. (2000). Associations and interactions between bare lymphocyte syndrome factors. Mol. Cell. Biol. 20, 6587-6599.
6. Gill, G. (2003). Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr. Opin. Genet. Dev. 13, 108-113.
7. Gill, G. (2005). Something about SUMO inhibits transcription. Curr. Opin. Genet. Dev. 15, 536-541.
8. Gomez, J.A., Majumder, P., Nagarajan, U.M., and Boss, J.M. (2005). X box-like sequences in the MHC class II region maintain regulatory function. J. Immunol. 175, 1030-1040.
9. Gregoire, S., Tremblay, A.M., Xiao, L., Yang, Q., Ma, K., Nie, J., Mao, Z., Wu, Z., Giguere, V., and Yang, X.J. (2006). Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation. J. Biol. Chem. 281, 4423-4433.
10. Hake, S.B., Masternak, K., Kammerbauer, C., Janzen, C., Reith, W., and Steimle, V. (2000). CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation. Mol. Cell. Biol. 20, 7716-7725.
11. Hay, R.T. (2005). SUMO: a history of modification. Mol. Cell 18, 1-12.
12. Hietakangas, V., Anckar, J., Blomster, H.A., Fujimoto, M., Palvimo, J.J., Nakai, A., and Sistonen, L. (2006). PDSM, a motif for phosphorylation-dependent SUMO modification. Proc. Natl. Acad. Sci. USA 103, 45-50.
13. Johnson, E.S. and Blobel, G. (1999). Cell cycle-regulated attachment of the ubiquitin-related protein SUMO to the yeast septins. J. Cell Biol. 147, 981-994.
14. Kang, J., Gocke, C.B., and Yu, H. (2006). Phosphorylation-facilitated sumoylation of MEF2C negatively regulates its transcriptional activity. BMC Biochem. 7, 5.
15. Kotaja, N., Karvonen, U., Janne, O.A., and Palvimo, J. (2002). PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol. Cell. Biol. 22, 5222-5234.
16. Masternak, K., Peyraud, N., Krawczyk, M., Barras, E., and Reith, W. (2003). Chromatin remodeling and extragenic transcription at the MHC class II locus control region. Nat. Immunol. 4, 132-137.
17. Matt, T., Martinez-Yamout, M.A., Dyson, H.J., and Wright, P.E. (2004). The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2. Biochem. J. 381, 685-691.
18. Melchior, F., Schergaut, M., and Pichler, A. (2003). SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28, 612-618.
19. Mudhasani, R. and Fontes, J.D. (2002). The class II transactivator requires brahma-related gene 1 to activate transcription of major histocompatibility complex class II genes. Mol. Cell. Biol. 22, 5019-5026.
20. Nekrep, N., Fontes, J.D., Geyer, M., and Peterlin, B.M. (2003). When the lymphocyte loses its clothes. Immunity 18, 453-457.
21. Pichler, A., Gast, A., Seeler, J.S., Dejean, A., and Melchior, F. (2002). The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 108, 109-120.
22. Sachdev, S., Bruhn, L., Sieber, H., Pichler, A., Melchior, F., and Grosschedl, R. (2001). PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 15, 3088-3103.
23. Schmidt, D. and Muller, S. (2002). Members of the PIAS family act as SUMO ligases for c-jun and p53 and repress p53 activity. Proc. Natl. Acad. Sci. USA 99, 2872-2877.
24. Scholl, T., Mahanta, S.K., and Strominger, J.L. (1997). Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Proc. Natl. Acad. Sci. USA 94, 6330-6334.
25. Sharrocks, A.D. (2006). PIAS proteins and transcriptional regulation - more than just SUMO E3 ligases? Genes Dev. 20, 754-758.
26. Steimle, V., Otten, L.A., Zufferey, M., and Mach, B. (1993). Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75, 135-146.
27. Sternsdorf, T., Jensen, K., Reich, B., and Will, H. (1999). The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J. Biol. Chem. 274, 12555-12566.
28. Tatham, M.H., Jaffray, E., Vaughan, O.A., Desterro, J.M., Botting, C.H., Naismith, J.H., and Hay, R.T. (2001). Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276, 35368-35374.
29. van den Elsen, P.J., Holling, T.M., Kuipers, H.F., and van der Stoep, N. (2004). Transcriptional regulation of antigen presentation. Curr. Opin. Immunol. 16, 67-75.
30. Van Dyck, F., Delvaux, E.L., Van de Ven, W.J., and Chavez, M.V. (2004). Repression of the transactivating capacity of the oncoprotein PLAG1 by SUMOylation. J. Biol. Chem. 279, 36121-36131.
31. Wright, K.L. and Ting, J.P. (2006). Epigenetic regulation of MHCII and CIITA genes. Trends Immunol. 27, 405-412.
32. Yang, M., Hsu, C.T., Ting, C.Y., Liu, L.F., and Hwang, J. (2006). Assembly of a polymeric chain of SUMO1 on human topo-isomerase I in vitro. J. Biol. Chem. 281, 8264-8274.
33. Yang, S.H., Jaffray, E., Senthinathan, B., Hay, R.T., and Sharrocks, A.D. (2003). SUMO and transcriptional repression: dynamic interactions between the MAP kinase and SUMO pathways. Cell Cycle 2, 528-530.
34. Zhao, X., Sternsdorf, T., Bolger, T.A., Evans, R.M., and Yao, T.P. (2005). Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. Mol. Cell. Biol. 25, 8456-8464.
35. Zhu, X.S., Linhoff, M.W., Li, G., Chin, K.C., Maity, S.N., and Ting, J.P. (2000). Transcriptional scaffold: CIITA interacts with NFY, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol. Cell. Biol. 20, 6051-6061.